As part of a safety review update on cardiovascular events and Benicar (olmesartan), the U.S. Food and Drug Administration states Benicar’s benefits “continue to outweigh its potential risks when used for the treatment of patients with high blood pressure according to the drug label http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&SearchTerm=benicar&SearchType=BasicSearch. Read more at http://www.fda.gov/Drugs/DrugSafety/ucm251268.htm.
© 2020 HealthCom Media
All rights reserved. No part of this website or publication may be reproduced, stored, or transmitted in any form or by any means, electronic or mechanical, including photocopy, recording, or any information storage and retrieval system, without permission in writing from the copyright holder